NASDAQ · Healthcare · Drug Manufacturers—General
Gilead Sciences, Inc. (GILD)
As of Sep 25, 4:00 PM ET, Gilead Sciences (GILD) last traded at $150.93, up 0.83% on the day. Its TickerHum research score is 42/100 (average). It reported revenue of $30.46B for the twelve months ending 2026-06-30, up 5.5% year over year, with a -8.2% operating margin.
Ratings
- Valuation: 57/100 — Strongest input: free-cash-flow yield 6.9 %. Weakest: price / earnings (ttm) Negative earnings.
- Growth: 20/100 — Strongest input: revenue growth (ttm, yoy) +5.5 %. Weakest: diluted eps growth (ttm, yoy) -152.6 %.
- Profitability: 1/100 — Strongest input: operating margin -8.2 %. Weakest: return on equity -27.4 %.
- Financial health: 21/100 — Strongest input: long-term debt / equity 2.01. Weakest: cash / long-term debt 0.13.
- Momentum: 74/100 — Strongest input: 3-month return +18.0 %. Weakest: 6-month return +10.3 %.
- Attention: 56/100 — Strongest input: headlines in the last 7 days 34. Weakest: volume vs 3-month average 0.8x.
- Risk: 76/100 — Strongest input: annualised volatility (1y) 26.4 %. Weakest: max drawdown (1y) -22.0 %.
- Data confidence: 90/100 — Strongest input: latest financial period age (days) 59 d. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $30.46B | TTM ending 2026-06-30 · 10-Q |
| Revenue growth | 5.5% | TTM ending 2026-06-30 · 10-Q |
| Net income | -$3.24B | TTM ending 2026-06-30 · 10-Q |
| Diluted EPS | -$2.65 | TTM ending 2026-06-30 · 10-Q |
| Operating margin | -8.2% | TTM ending 2026-06-30 · 10-Q |
| Net margin | -10.6% | TTM ending 2026-06-30 · 10-Q |
| Free cash flow | $12.94B | TTM ending 2026-06-30 · 10-Q |
| Cash | $3.18B | as of 2026-06-30 · 10-Q |
| Long-term debt | $23.83B | as of 2026-06-30 · 10-Q |
| Debt / equity | 2.01 | as of 2026-06-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000882095).
Compare Gilead Sciences with its closest competitors
- Gilead Sciences vs Pfizer (GILD vs PFE) — Same industry (Drug Manufacturers—General); market cap 0.87x; shares: oncology
- Gilead Sciences vs Amgen (GILD vs AMGN) — Same industry (Drug Manufacturers—General); market cap 1.2x; shares: oncology
- Gilead Sciences vs Bristol-Myers Squibb (GILD vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.69x; shares: oncology
- Gilead Sciences vs Merck & Co. (GILD vs MRK) — Same industry (Drug Manufacturers—General); market cap 2.0x; shares: oncology
- Gilead Sciences vs AbbVie (GILD vs ABBV) — Same industry (Drug Manufacturers—General); market cap 2.5x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.